Date: 2015-07-17
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: C2N Diagnostics (USA - MO) AbbVie (USA - IL)
Product: C2N-8E12 - recombinant humanized anti-tau antibody
Action
mechanism: monoclonal antibody. C2N-8E12 is a humanized antibody targeting the tau protein found in neurofibrillary tangles in the brain of patients with tauopathies such as progressive supranuclear palsy and Alzheimer\'s disease.
Disease: progressive supranuclear palsy
Therapeutic area: Rare diseases - Neurodegenerative diseases - Neurological diseases
Country: USA
Trial
details: This study will evaluate the safety and tolerability (maximum tolerated dose (MTD) within the specified dosing range) of single intravenous (IV) infusion of C2N-8E12 in patients with progressive supranuclear palsy (PSP). (NCT02494024)
Latest
news: * On July 17, 2015, C2N Diagnostics and AbbVie announced that they have begun a Phase 1 clinical study of C2N-8E12 in patients with progressive supranuclear palsy. The Phase 1 study is a randomized, double-blind, placebo-controlled, single ascending dose, multicenter study that will evaluate the safety, tolerability and pharmacokinetics of C2N-8E12 in an estimated 32 subjects with progressive supranuclear palsy.
